Home   Distributors   Careers   Contact

DynamX

DESyne X2

• Eliminates the need for a primer coating
• Achieves a bare metal surface within 6–9 months
• Superior efficacy and excellent clinical safety

stent

Desyne BD | Novolimus Eluting Coronary Stent System

BRS Not Created Equal

DESolve Cx PLUS

DESolve NXT

• State-of-the-art NOVOLIMUS™ eluting scaffold system
• Next generation in scaffold technology

learn more

Desolve | Novolimus Eluting Bioresorbable Coronary Scaffold System

• Improved performance
• Superior clinical efficacy and safety

learn more

The State of the Art Drug Eluting Stent

Unique Drug Agent Novolimus

Advanced Drug Coating/Polymer Technology
• Lowest polymer coating load2
• Reduced risk of adverse clinical events3
• Reliable performance with lower drug dose

Unique Drug Agent Novolimus

• Proprietary drug facilitates superior clinical efficacy5
• Established safety and performance
• Clinically proven 'olimus' drug family

About Elixir

Innovating Vascular Restoration™

Leading the Way to Next Generation DES Platforms

Elixir Medical Corporation, a privately held company headquartered in Milpitas, CA, specializes in developing products that combine state-of-the-art technology with advanced pharmaceuticals to provide innovative treatment solutions to patients worldwide. Learn More...

 

In the News

Elixir Medical at TCT 2017

Pre-Register for the Symposium

Transforming PCI

DynamX is not available for sale. 1Data based on pre-clinical studies.

 

 

Introducing DynamX™ – Metallic DES With Adaptive Remodeling

Professor Verheye Presents DESolve at PCR 2017

View PCR 2017 Presentation Slides

Professor Verheye

View the Presentation on PCR Online

Elixir shows resolve | BioWorld Medtech | Vol 21, Issue 200

Click here to view the full article